Skip to content

Efficacy and Safety of Fractional 1064 nm Picosecond Laser for the Treatment of Mammoplasty Scar in Asians: A Prospective, Randomized Comparative Study

Efficacy and safety of using fractional picosecond laser 1064-nm for treatment of Mammoplasty scar in Asians: A prospective, randomized comparative study

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
TCTR
Registry ID
TCTR20210730001
Enrollment
24
Registered
2021-07-30
Start date
2020-11-09
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with mammoplasty scar s on both sided of breast mammoplasty scar, picosecond laser, fractional 1064 nm picosecond laser

Interventions

Treatment: 0.8 J/cm2, repetitive rate 10 Hz, spot size 8 mm, pulse width 750 ps, 2-5 passes Early intervention: 0.6 J/cm2, repetitive rate 10 Hz, spot size 8 mm, pulse width 750 ps, 2 passes Endpoi
Experimental Device,No Intervention No treatment
Picosecond laser 1064 nm,Control

Sponsors

Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand
Lead Sponsor
Lasermed Co., Ltd.
Collaborator

Eligibility

Sex/Gender
Female
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Female aged 18-60 years 2. Had hypertrophic scars on both breasts after breast surgery and did not receive any hypertrophic scar treatments in the past 6 months prior to enrolment or did bilateral breast surgery within 1 month prior to enrollment. 3. Conducted breast surgery due to breast cancer, breast augmentation, or breast reduction

Exclusion criteria

Exclusion criteria: 1. Patients having infection or active wound in the test area 2. Patients with herpes infection or having a history of herpes infection 3. Immunocompromised patients 4. Patients with connective tissue disease 5. Receiving immunosuppressive drugs 6. Pregnancy

Design outcomes

Primary

MeasureTime frame
Skin texture (Roughness) Baseline, 1 , 3, and 6 months after treatment Antera analysis

Secondary

MeasureTime frame
Scar volume Baseline, 1 , 3, and 6 months after treatment Antera analysis,Skin pigmentation Baseline, 1 , 3, and 6 months after treatment Antera analysis,Physician improvement scale Baseline, 1 , 3, and 6 months after treatment 6 points scale,Patient and Observer Scar Assessment Scale Baseline, 1 , 3, and 6 months after treatment POSAS score,Safety Baseline, 1 , 3, and 6 months after treatment Adverse event

Countries

Thailand

Contacts

Public ContactWoraphong Manuskiatti

Faculty of Medicine Siriraj Hospital, Mahidol University

woraphong.man@mahidol.ac.th66819150555

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026